Developing a new vaccine approach for HIV prevention
Synthetic DNA-launched and adjuvanted Env immunogens for HIV
This study is working on a new type of vaccine for HIV that uses DNA to help your immune system fight the virus better, and it's designed for anyone interested in preventing HIV infection.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11011256 on NIH RePORTER |
What this research studies
This research focuses on creating a protective vaccine for HIV using a DNA platform that can effectively stimulate the immune system. It aims to enhance the body's response to HIV by delivering specific proteins and molecular adjuvants that boost the production of neutralizing antibodies and T cell responses. The approach has shown promise in previous studies, where DNA-launched nanoparticle vaccines induced strong immune responses in animal models. By improving the design and delivery of these vaccines, the research seeks to provide a more effective strategy for preventing HIV infection.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk of HIV exposure or those who are HIV-negative but may benefit from preventive measures.
Not a fit: Patients who are already HIV-positive or those with severe immunocompromised conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective vaccine that significantly reduces the risk of HIV infection.
How similar studies have performed: Previous research has shown success with similar DNA vaccine approaches, indicating potential for this novel strategy.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Weiner, David B. — Wistar Institute
- Study coordinator: Weiner, David B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.